Improving patient outcomes in pulmonary hypertension

In recent years we have come a long way in our understanding of pulmonary hypertension (PH). As a result of ever-increasing experience in treating pulmonary arterial hypertension (PAH), and the availability of new treatment options, there have been continual improvements in patient outcomes. As patients are today living longer with this disease, there is now a focus on assessing the impact that PAH has on quality of life, and increased recognition that PAH management must aim to reduce this impact. The articles in this issue of European Respiratory Review discuss practical aspects of managing patients with PH, look at the disease from the patient perspective, and review some of the latest strategies for diagnosis and treatment of this group of conditions. The authors, each of them experts in the field of PH, delivered presentations at the 14th International Pulmonary Hypertension Forum held in March 2015 in Copenhagen, Denmark, upon which this series of reviews is based. The updated management of PAH patients is leading to improvements in quality of life and outcome <http://ow.ly/TAvMf> The 14th International Pulmonary Hypertension Forum on which the content of this review series is based was sponsored by Actelion Pharmaceuticals Ltd (Allschwil, Switzerland). The authors would like to thank Kate Bradford from PAREXEL (Worthing, UK) for medical writing assistance, funded by Actelion Pharmaceuticals Ltd.